Acadia Pharmaceuticals
ACAD
184 hedge funds and large institutions have $2.49B invested in Acadia Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 39 closing their positions.
40% more capital invested
Capital invested by funds: $1.79B → $2.49B (+$706M)
38% more call options, than puts
Call options by funds: $65.2M | Put options by funds: $47.3M
2.35% more ownership
Funds ownership: 93.65% → 96.01% (+2.4%)
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 39
2% less funds holding
Funds holding: 187 → 184 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$51.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$37.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$19M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$65.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.3M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$16.1M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.6M |
| 5 |
O
OppenheimerFunds
New York
|
-$11.7M |
ACAD Hedge Fund Activity: Q3 2018 in Review
184 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2018, worth a combined $2.49B — up 40% from $1.79B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ACAD and 37 opened new positions — a net loss of 2 holders — while 55 trimmed existing stakes and 56 added.
The largest buyer was First Trust Advisors, adding an estimated $51.4M. The largest seller was OrbiMed, exiting entirely with an estimated $65.4M sold.
- 184 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2018, down from 187 in Q2 2018.
- Funds reported $2.49B of Acadia Pharmaceuticals stock for Q3 2018, up 40% quarter-over-quarter.
- 37 funds opened new Acadia Pharmaceuticals positions in Q3 2018 and 39 closed out, a net change of -2 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2018 was First Trust Advisors, an estimated $51.4M added.
- The largest Acadia Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $65.4M sold.
Based on aggregated 13F filings for Q3 2018.